GRAIL INC (GRAL)
Health Care · multi-cancer early detection / liquid biopsy diagnostics · NASDAQ
GRAIL is developing Galleri, a blood-based multi-cancer early detection test designed to detect many types of cancer from a single draw and pinpoint the tissue of origin, pending FDA approval.
What GRAIL INC does
GRAIL is a commercial-stage healthcare company developing Galleri, a multi-cancer early detection test that screens for many types of cancer from a single blood draw and identifies the cancer signal of origin with high positive predictive values and low false positive rates. The company has conducted large clinical programs with over 385,000 participants and recently submitted its pre-market approval application to the FDA. GRAIL is focused on shifting the paradigm in early cancer detection at population scale through partnerships with healthcare systems, employers, digital health platforms, payors, and life insurance providers.
Themes: ["multi-cancer early detection (MCED)","cancer screening / prevention","liquid biopsy / blood-based diagnostics","genomic medicine","regulatory approval pathway (FDA PMA)"]
Fundamentals
- Price$75.79 as of 2026-07-09 close
- Market cap$3.3B as of 2026-07-10
- 1-year return+79.9% as of 2026-07-09 close
- Net margin-253.2% as of 2026-07-10
- Gross margin+49.3% as of 2026-07-10
- ROE-16.4% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)+19.4% as of 2026-07-10
- Revenue CAGR (3y)+25.7% SEC XBRL
- Beta2.32 as of 2026-07-10
Key risks (from latest filing)
["Regulatory uncertainty: FDA pre-market approval application outcome and timing are not guaranteed; failure to obtain approval would prevent commercialization of Galleri","Reimbursement and adoption risk: successful commercialization depends on payer reimbursement, clinical adoption by healthcare providers, and patient demand—all of which remain uncertain despite clinical validation","Significant ongoing losses: the company is unprofitable with a net margin of -253.22%, with substantial R&D, clinical trial, and operational costs consuming revenue; cash burn and path to profitability are major risks"]
Competitors & peers
- Guardant Health (GH)
- Exact Sciences (EXAS)
- Invitae (NVTA)
- Foundation Medicine
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.